Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652 - PubMed (original) (raw)
Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652
Justine M Kent et al. Psychopharmacology (Berl). 2002 Dec.
Abstract
Rationale: Although selective serotonin reuptake inhibitors (SSRIs) are widely used in the treatment of anxiety and depressive disorders, the occupancy of the serotonin reuptake transporter (SERT) achieved in humans at typical clinical doses by these agents remains poorly characterized.
Objective: The purpose of this study was to determine the occupancy of the SERT achieved in vivo by the SSRI paroxetine in social phobia patients at typical antianxiety doses.
Methods: Measures of SERT availability were obtained with positron emission tomography and the SERT radiotracer [(11)C](+)-McN 5652 in five patients with social phobia before and during treatment with paroxetine at usual therapeutic doses (20-40 mg per day).
Results: Occupancy of the SERT by paroxetine was high in all subjects and in all regions measured after 3-6 months of continuous treatment.
Conclusions: The results of this study in an anxiety disorder sample are consistent with previously reported results in a depressed sample and suggest that paroxetine at therapeutic doses achieves very high occupancy levels of the SERT.
Similar articles
- Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.
Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S. Meyer JH, et al. Am J Psychiatry. 2004 May;161(5):826-35. doi: 10.1176/appi.ajp.161.5.826. Am J Psychiatry. 2004. PMID: 15121647 - Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors.
Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, Anand A, Van Dyck CH, Baldwin RM, Seibyl JP, Charney D, Innis RB. Kugaya A, et al. Biol Psychiatry. 2004 Oct 1;56(7):497-502. doi: 10.1016/j.biopsych.2004.07.001. Biol Psychiatry. 2004. PMID: 15450785 Clinical Trial. - [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats.
Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S. Ginovart N, et al. Synapse. 2003 Feb;47(2):123-33. doi: 10.1002/syn.10155. Synapse. 2003. PMID: 12454950 - Neuropharmacology of paroxetine.
Nemeroff CB, Owens MJ. Nemeroff CB, et al. Psychopharmacol Bull. 2003 Spring;37 Suppl 1:8-18. Psychopharmacol Bull. 2003. PMID: 14566196 Review. - The role of drug therapy in social phobia.
Lydiard RB. Lydiard RB. J Affect Disord. 1998 Sep;50 Suppl 1:S35-9. doi: 10.1016/s0165-0327(98)00090-1. J Affect Disord. 1998. PMID: 9851577 Review.
Cited by
- Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy.
Hjorth O, Frick A, Gingnell M, Engman J, Björkstrand J, Faria V, Alaie I, Carlbring P, Andersson G, Jonasson M, Lubberink M, Antoni G, Reis M, Wahlstedt K, Fredrikson M, Furmark T. Hjorth O, et al. Transl Psychiatry. 2022 Oct 7;12(1):436. doi: 10.1038/s41398-022-02187-3. Transl Psychiatry. 2022. PMID: 36202797 Free PMC article. Clinical Trial. - Cerebellar heterogeneity and its impact on PET data quantification of 5-HT receptor radioligands.
Ganz M, Feng L, Hansen HD, Beliveau V, Svarer C, Knudsen GM, Greve DN. Ganz M, et al. J Cereb Blood Flow Metab. 2017 Sep;37(9):3243-3252. doi: 10.1177/0271678X16686092. Epub 2017 Jan 11. J Cereb Blood Flow Metab. 2017. PMID: 28075185 Free PMC article. - Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [(11)C]MADAM PET study.
Finnema SJ, Halldin C, Bang-Andersen B, Bundgaard C, Farde L. Finnema SJ, et al. Psychopharmacology (Berl). 2015 Nov;232(21-22):4159-67. doi: 10.1007/s00213-015-3961-7. Epub 2015 May 17. Psychopharmacology (Berl). 2015. PMID: 25980484 - Serotonin and mental disorders: a concise review on molecular neuroimaging evidence.
Lin SH, Lee LT, Yang YK. Lin SH, et al. Clin Psychopharmacol Neurosci. 2014 Dec;12(3):196-202. doi: 10.9758/cpn.2014.12.3.196. Epub 2014 Dec 26. Clin Psychopharmacol Neurosci. 2014. PMID: 25598822 Free PMC article. Review. - A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy.
Coplan JD, Gopinath S, Abdallah CG, Berry BR. Coplan JD, et al. Front Behav Neurosci. 2014 May 20;8:189. doi: 10.3389/fnbeh.2014.00189. eCollection 2014. Front Behav Neurosci. 2014. PMID: 24904340 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical